EP0105923A4 - Method and composition for elevated lipid quality control materials. - Google Patents
Method and composition for elevated lipid quality control materials.Info
- Publication number
- EP0105923A4 EP0105923A4 EP19830901778 EP83901778A EP0105923A4 EP 0105923 A4 EP0105923 A4 EP 0105923A4 EP 19830901778 EP19830901778 EP 19830901778 EP 83901778 A EP83901778 A EP 83901778A EP 0105923 A4 EP0105923 A4 EP 0105923A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- serum
- plasma
- lipoproteins
- alpha
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Definitions
- This invention relates to the preparation of clinical chemistry controls and standards.
- it relates to the manufacture of controls and standards having cholesterol and triglyceride concentrations above the normal mean for human serum.
- Clinical chemistry assays for lipids such- as cholesterol and triglycerides in serum are commonly conducted in the laboratory. The accuracy and precision of these assays are continuously evaluated by conducting the test sample assays in tandem with controls or calibrators.
- the controls and cali ⁇ brators contain a known amount of lipid and thus provide results against which the continuing performance of the assays can be compared.
- quantitative assays depend upon the preparation of a standard curve. Such curves are prepared by assaying a plurality of standards different predetermined quantities of the various lipids.
- controls, standards and calibrators will be col ⁇ lectively referred to as quality control materials.
- Lipid-containing control materials * for the assay of human test samples are designed to mimic the performance of the test samples as closely as possible.
- cholesterol and triglyceride supplements are added to a base plasma or serum they are supplied as complexes with protein, just as they are found in test samples.
- lipoproteins are available from a wide variety of sources such as plasma or eggs, and they have the additional advantage of water solubility.
- lipoproteins as carrier-solubil- izers for cholesterol or triglycerides
- fragility of the protein-lipid complexes. They are sensitive to the pH, ionic strength and temperature of their environment and to abuse such as shear and concentration effects.
- One particular problem has been the reduction in lipoprotein water solubility brought about by lyophilization of plasma or serum containing quality control materials. This reduction in solubility is evidenced by the development of turbidity in the materials. This is obviously unsatisfactory because the precipitated lipids will perform differently in lipid assays when compared with test
- U.S. Patents 4,045,176 and 3,955,925 disclose two types o quality control materials which are optically clear upon reconstitution and which contain normal or elevated concentra ⁇ tions of lipids.
- One control material was made by adding high density human lipoproteins (alpha lipoproteins) to substan ⁇ tially human serum. The high density lipoproteins were stable
- a second control material was made by adding isolated, non-primate lipoproteins to substantially human serum. Accord ⁇ ing to the patentees it was not necessary to first separate the high and low density lipoproteins as was required when using human lipoproteins, and that the low density non-primate lipo ⁇ proteins could be included without substantial adverse effect. Bovine lipoproteins were most preferred.
- U.S. Patents 4,045,176 and 3,955,925 teach that isolated bovine lipoprotein can be added to human blood serum without adverse effect, the same could not be said for the addition of isolated bovine lipoprotein to serum other than that from humans.
- U.S. Patent 3,764,556 teaches isolating cholesterol-rich fractions from egg or human plasma and adding them to bovine or equine sera. This was done to enhance the normally low triglyceride and cholesterol concentrations in bovine and equine sera, thereby.enabling their use as normal o elevated lipid controls in the assay of human serum test sam- ples.
- an animal serum or plasma-based lipid quality control material having cholesterol and triglyceride concentrations of at least the levels found in normal human plasma or serum.
- a stable quality control material can be prepared by combining a lipoprotein concentrate from animals with an animal sera if the lipoprotein concentrate is enriched in high density or alpha lipoproteins. Applicants have found that it is essential to remove animal chylomicrons as well as low den ⁇ sity and very low density lipoproteins from animal lipoprotein concentrates before supplementing animal serum with the concen ⁇ trate.
- the objects of this invention are achieved by mixing substantially normal animal plasma or serum with animal high density lipoproteins which are substantially free of animal chylomicrons and low density and very low density lipo ⁇ proteins.
- the resulting novel quality control materials shoul be substantially free of human plasma protein fractions. They can be reconstituted after lyophilization to yield clear solutions.
- the animal plasma or serum chosen as raw material for preparation of the lipoprotein concentrate is not critical, although for the purposes herein "animal” is intended to exclude all primates. Suitable sources are cows, horses, chickens, sheep and swine. While the alpha lipoprotein conten of animal plasma varies somewhat this should not be a major factor in selecting a suitable source other than from consider ⁇ ation of yield. Bovine and equine serum is most suitable, although bovine is preferred.
- the animal high density lipoproteins are obtained by known processes.
- the lipoprotein II fraction disclosed in Proksch et al. “Clin. Chem.” 22/8:1302-1305 (1976) is suit ⁇ able, as is the bovine high density lipoprotein fraction pro ⁇ quizzed in accordance with Jonas, "J. Biological Chemistry” 247(23) :7767-7772 (1972) or Example 1 of U.S. Patent 4,045,176.
- Animal lipoprotein concentrates useful herein will contain fr about 80% to 100% alpha lipoproteins by lipid electrophoresis (Sebia electrophoresis cell) and, if purified to a lipoprotein concentrate essentially free of other proteins, serum should have a specific gravity of greater than about 1.065. More preferably the lipoprotein content of the fractions will be about 90% to 95% alpha lipoproteins, preferably about 90%, wit the remainder being pre-beta and beta globulins. The less the amount of beta and pre-beta lipoproteins the more suitable the concentrate will be from the standpoint of clarity. However, very high alpha lipoprotein purity raises costs and increases the amount of concentrate needed to supply a given triglyceride value.
- Such concentrates will generally contain about from 0.30 - 0.50 g triglyceride/liter and about from 10 to 15 g cholesterol/liter. Cholesterol and cholesterol esters will constitute about from 20% to 45% by weight of the lipoprotein, and triglycerides about 15% to 30% by weight. Generally, one will select concentrates having the highest alpha lipoprotein concentration, followed by selection on the basis of the high ⁇ est cholesterol content.
- Non-lipoprotein serum proteins which are lyophilization stable, e.g., X ⁇ -globulins, can be included in the lipoprotein concentrates used herein. It is not desir ⁇ able to have large amounts of gamma globulin, fibrinogen or albumin in the concentrate.
- pooled animal serum will function as the base to which the concentrate is added. It is preferred to use serum from an animal having a low beta and pre-beta lipoprotein content when compared with human plasma. Suitable sources are bovine, equine and sheep serum, with bovine being preferred. Commercially available animal plasma is easily converted to serum by clotting with calcium and thrombin and removing the clot by centrifugation, along with any remaining contaminant blood cells. Serum is stored frozen. The serum is a clear, amber fluid from which cellular elements and most fibrinogen have been removed, and it contains components of .clinical interest in assays other than those for lipids, e.g., salts, enzymes, glucose, protein and urea.
- lipids e.g., salts, enzymes, glucose, protein and urea.
- the serum should be sup ⁇ plemented with any of these components which are clinically significant if it is normally deficient in them, as is conven ⁇ tional practice in the art.
- the cholesterol and triglyceride components are supplemented b adding the lipoprotein concentrate described above to the serum.
- the base serum may also be processed to reduce its bet and pre-beta lipoprotein content, e.g. by selective precipita ⁇ tion with heparin or dextran sulfate in accordance with known processes. All serum starting materials should be free of chylomicrons.
- the general process for making quality control materials ordinarily starts with thawing and pooling sera which had been prepared and stored previously.
- Pooling means combining the sera from a plurality of separate donors into batches that can be economically processed on a commercial scale.
- the pooled serum is filtered through successively finer filters, termin ⁇ ating in filtration through a 0.3u pore diameter filter.
- albumin, cholesterol and triglycerides are added to bring the serum up to the desired protein, cholesterol and triglycerides concentrations.
- the alpha lipoprotein concen- trates can provide all cholesterol which is needed and in most cases all the protein and triglycerides as well. If not, then protein and triglycerides can be supplemented from the exogen ⁇ ous sources. Any other constituents that are present in insufficient concentration are then added as required.
- the pooled, adjusted serum is filled into vials, lyophilized and sealed.
- the amount of concentrate to be added to the serum depend upon the amount of triglycerides and cholesterol present in the base serum and in the concentrate. These quantities can be measured conventionally and the proper quantity of concentrate to be added readily calculated. Since the concentrate is more suitable for cholesterol enhancement this will be the control ⁇ ling component. Generally, the high density lipoprotein con ⁇ centrate will contain about from 20% to 45% cholesterol by weight of lipoprotein, but this will vary depending upon the species from which the lipoprotein was obtained and the parti ⁇ cular lipoprotein fraction obtained by the concentration method employed in that particular instance.
- the concentrate is typically added to bring the base serum cholesterol content at least up to the level of normal human serum, i.e. about from 1.2 to 2.5 g cholesterol (free plus ester)/ liter.
- Triglyceride should be brought up to about from 0.3 to 0.5 g/liter if possible without introducing more cho ⁇ lesterol than is desired.
- This invention has its principal utility in making hypercholesterolemic sera, i.e., sera in which the cholesterol content is about from 2 ⁇ 5 to 4.5 g/liter. Sera having concentrations throughout this range may be lyophilized and reconstituted to optically satisfactory solutions.
- the pooled animal sera produced by combining the above- described concentrates with an animal serum base contain a con ⁇ centration of lipoprotein lipid in excess of that found in pooled serum from animals of the same species.
- the composi ⁇ tions of this invention include pooled animal sera, particu ⁇ larly that from cattle and horses, which contain lipoprotein- bound cholesterol at a cholesterol concentration of greater than about 1.2g/l, preferably greater than about 2.0 g/1 and up to about 4.5g/1.
- novel products of this invention contain an enriched proportion of alpha lipoproteins, i.e., a proportion by weight of total lipoproteins and by weight/volume above that found in normal pooled serum and frequently a level above that in the serum of hyper ⁇ holesterolemi ⁇ specimens of the animal in question. Frequently the alpha lipoprotein concentration will be in excess of 25% weight/volume above that of normal pooled plasma or serum.
- the level of alpha lipoprotein also may be described in terms of the weight ratio of alpha lipoproteins to beta and pre-beta lipoproteins. In the case of bovine sera, the ratio of alpha lipoproteins to beta and pre-beta lipopro ⁇ teins is at least 3.75:1, usually about 4:1.
- Sheep sera havin a ratio of at least 3.1 to 1, preferably about 3.5 to 1 are also useful but not as desirable as the more conveniently available bovine serum.
- the lipid, e.g. cholesterol concen ⁇ tration is generally at least about 25% by weight/volume above that of normal pooled plasma or serum. - li ⁇
- lt is contemplated that cholesterol concentrates from on animal species can be added to a base serum of another animal.
- bovine concentrates can be used with normal, pooled horse serum.
- the products herein are preferably substantially free of human lipoproteins, contaminant human lipoproteins may accompany supplemental analytes such as human proteins added to adjust analyte concentrations as described above.
- the former assay demonstrated only a faint band at the very low density and chylomicron positions, but had a strong, broad stain identified as high density lipoprotein shading faintly into low density lipoprotein.
- This concentrate was clarified by filtration through a 0.3u pore diameter filter to a final volume of 49,800 ml.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Quality control materials are produced by combining non-primate animal sera or plasma with a non-animal alpha lipoprotein concentrate and lyophilizing. The resulting novel compositions are stable, optically clear upon reconstitution and contain no potentially hepatitis infective human plasma protein fractions.
Description
METHOD AND COMPOSITION FOR ELEVATED LIPID QUALITY CONTROL MATERIALS
BACKGROUND ART
This invention relates to the preparation of clinical chemistry controls and standards. In particular it relates to the manufacture of controls and standards having cholesterol and triglyceride concentrations above the normal mean for human serum.
Clinical chemistry assays for lipids such- as cholesterol and triglycerides in serum are commonly conducted in the laboratory. The accuracy and precision of these assays are continuously evaluated by conducting the test sample assays in tandem with controls or calibrators. The controls and cali¬ brators contain a known amount of lipid and thus provide results against which the continuing performance of the assays can be compared. In addition, quantitative assays depend upon the preparation of a standard curve. Such curves are prepared by assaying a plurality of standards
different predetermined quantities of the various lipids. Hereinafter controls, standards and calibrators will be col¬ lectively referred to as quality control materials.
Since the amount of cholesterol and triglycerides in a patient's serum is used for clinical diagnosis and drug therapy monitoring-, it is necessary that the quantity be accurately and consistently determined. Thus it is important that day-to-day or test-to-test variation in the assay be carefully controlled.
Lipid-containing control materials*for the assay of human test samples are designed to mimic the performance of the test samples as closely as possible. Thus when cholesterol and triglyceride supplements are added to a base plasma or serum they are supplied as complexes with protein, just as they are found in test samples. Such lipoproteins are available from a wide variety of sources such as plasma or eggs, and they have the additional advantage of water solubility.
A disadvantage of using lipoproteins as carrier-solubil- izers for cholesterol or triglycerides is the fragility of the protein-lipid complexes. They are sensitive to the pH, ionic strength and temperature of their environment and to abuse such as shear and concentration effects. One particular problem has been the reduction in lipoprotein water solubility brought about by lyophilization of plasma or serum containing quality control materials. This reduction in solubility is evidenced by the development of turbidity in the materials. This is obviously unsatisfactory because the precipitated lipids will perform differently in lipid assays when compared with test
O
samples containing native lipoproteins, the control materials will not be homogeneous and the tubidity will interfere with analytical equipment such as spectrophotometers. The prep¬ aration of a lipoprotein-containing control material which can be lyophilized and reconstituted to a clear solution has been particular focus of the art.
Proksch et al, "Clin. Chem. " 22/4:456-460 (1976) disclose preparing an optically clear lyophilized human serum as a control. This was done by precipitating pre-beta and beta- lipoproteins from human serum with dextran sulfate, removing the precipitate and lyophilizing the supernatant. The diffi¬ culty with this approach was that precipitating these lipopro¬ teins decreased the cholesterol and triglyceride levels to about 25% of the original values. This was understandable whe it is considered that 60-80% of the total weight of lipoprotei in human serum consists of very low density (pre-beta) or low density (beta) lipoproteins, and these lipoproteins are known to be the principal plasma carriers for cholesterol and tri¬ glycerides. Thus, this control per se was not useful as a control for normal or elevated lipid concentrations in human serum.
U.S. Patents 4,045,176 and 3,955,925 disclose two types o quality control materials which are optically clear upon reconstitution and which contain normal or elevated concentra¬ tions of lipids. One control material was made by adding high density human lipoproteins (alpha lipoproteins) to substan¬ tially human serum. The high density lipoproteins were stable
O
to lyophilization, yet carried sufficient lipid to enable the preparation of an elevated lipid control.
A second control material was made by adding isolated, non-primate lipoproteins to substantially human serum. Accord¬ ing to the patentees it was not necessary to first separate the high and low density lipoproteins as was required when using human lipoproteins, and that the low density non-primate lipo¬ proteins could be included without substantial adverse effect. Bovine lipoproteins were most preferred.
While U.S. Patents 4,045,176 and 3,955,925 teach that isolated bovine lipoprotein can be added to human blood serum without adverse effect, the same could not be said for the addition of isolated bovine lipoprotein to serum other than that from humans. U.S. Patent 3,764,556 teaches isolating cholesterol-rich fractions from egg or human plasma and adding them to bovine or equine sera. This was done to enhance the normally low triglyceride and cholesterol concentrations in bovine and equine sera, thereby.enabling their use as normal o elevated lipid controls in the assay of human serum test sam- ples. Use of an animal base serum reduced the cost of the con¬ trols and, when egg lipoprotein was used, eliminated the hepa¬ titis risk associated with human serum. However, this patent also taught that the cholesterol-rich fraction obtained from bovine or horse sera (as opposed to human) contains low cho¬ lesterol levels and, more importantly, the fraction tends to become insoluble after addition to animal sera.
It would be desirable to prepare a control serum that is free of human serum or plasma lipoprotein fractions but which,
contains normal or elevated triglyceride and cholesterol con¬ centrations. The use of an egg lipoprotein concentrate with a non-primate base is not practical; U.S. .Patent 4,045,176 dis¬ closes that the egg yolk fraction of U.S. Patent 3,764,556 must be used the same day it is prepared since a precipitate forms upon freezing and thawing. In addition, the egg yolk extract does not supply significant amounts of cholesterol.
Accordingly, it is an object of this inveniton to prepare an animal serum or plasma-based lipid quality control material having cholesterol and triglyceride concentrations of at least the levels found in normal human plasma or serum.
It is a further object of this invention to eliminate potentially hepatitis infective human plasma or serum protein ' components from controls and standards.
It is an additional object to provide an animal serum or plasma-based lipid quality control material which may be lyo¬ philized and reconstituted to a substantially clear solution.
These and other objects will be apparent from consideratio ■ ., of this specification as a whole.
SUMMARY OF THE INVENTION Applicants have discovered that, contrary to the teachings of the art, a stable quality control material can be prepared by combining a lipoprotein concentrate from animals with an animal sera if the lipoprotein concentrate is enriched in high density or alpha lipoproteins. Applicants have found that it is essential to remove animal chylomicrons as well as low den¬ sity and very low density lipoproteins from animal lipoprotein
concentrates before supplementing animal serum with the concen¬ trate.
Accordingly, the objects of this invention are achieved by mixing substantially normal animal plasma or serum with animal high density lipoproteins which are substantially free of animal chylomicrons and low density and very low density lipo¬ proteins. The resulting novel quality control materials shoul be substantially free of human plasma protein fractions. They can be reconstituted after lyophilization to yield clear solutions.
DETAILED DESCRIPTION OF INVENTION The animal plasma or serum chosen as raw material for preparation of the lipoprotein concentrate is not critical, although for the purposes herein "animal" is intended to exclude all primates. Suitable sources are cows, horses, chickens, sheep and swine. While the alpha lipoprotein conten of animal plasma varies somewhat this should not be a major factor in selecting a suitable source other than from consider¬ ation of yield. Bovine and equine serum is most suitable, although bovine is preferred.
The animal high density lipoproteins are obtained by known processes. For example, the lipoprotein II fraction disclosed in Proksch et al. , "Clin. Chem. " 22/8:1302-1305 (1976) is suit¬ able, as is the bovine high density lipoprotein fraction pro¬ duced in accordance with Jonas, "J. Biological Chemistry" 247(23) :7767-7772 (1972) or Example 1 of U.S. Patent 4,045,176.
Animal lipoprotein concentrates useful herein will contain fr
about 80% to 100% alpha lipoproteins by lipid electrophoresis (Sebia electrophoresis cell) and, if purified to a lipoprotein concentrate essentially free of other proteins, serum should have a specific gravity of greater than about 1.065. More preferably the lipoprotein content of the fractions will be about 90% to 95% alpha lipoproteins, preferably about 90%, wit the remainder being pre-beta and beta globulins. The less the amount of beta and pre-beta lipoproteins the more suitable the concentrate will be from the standpoint of clarity. However, very high alpha lipoprotein purity raises costs and increases the amount of concentrate needed to supply a given triglyceride value. Such concentrates will generally contain about from 0.30 - 0.50 g triglyceride/liter and about from 10 to 15 g cholesterol/liter. Cholesterol and cholesterol esters will constitute about from 20% to 45% by weight of the lipoprotein, and triglycerides about 15% to 30% by weight. Generally, one will select concentrates having the highest alpha lipoprotein concentration, followed by selection on the basis of the high¬ est cholesterol content. Non-lipoprotein serum proteins which are lyophilization stable, e.g., X^-globulins, can be included in the lipoprotein concentrates used herein. It is not desir¬ able to have large amounts of gamma globulin, fibrinogen or albumin in the concentrate.
Pooled animal serum will function as the base to which the concentrate is added. It is preferred to use serum from an animal having a low beta and pre-beta lipoprotein content when compared with human plasma. Suitable sources are bovine, equine and sheep serum, with bovine being preferred.
Commercially available animal plasma is easily converted to serum by clotting with calcium and thrombin and removing the clot by centrifugation, along with any remaining contaminant blood cells. Serum is stored frozen. The serum is a clear, amber fluid from which cellular elements and most fibrinogen have been removed, and it contains components of .clinical interest in assays other than those for lipids, e.g., salts, enzymes, glucose, protein and urea. The serum should be sup¬ plemented with any of these components which are clinically significant if it is normally deficient in them, as is conven¬ tional practice in the art. In accordance with this invention the cholesterol and triglyceride components are supplemented b adding the lipoprotein concentrate described above to the serum. The base serum may also be processed to reduce its bet and pre-beta lipoprotein content, e.g. by selective precipita¬ tion with heparin or dextran sulfate in accordance with known processes. All serum starting materials should be free of chylomicrons.
The general process for making quality control materials ordinarily starts with thawing and pooling sera which had been prepared and stored previously. Pooling means combining the sera from a plurality of separate donors into batches that can be economically processed on a commercial scale. The pooled serum is filtered through successively finer filters, termin¬ ating in filtration through a 0.3u pore diameter filter.
Then albumin, cholesterol and triglycerides are added to bring the serum up to the desired protein, cholesterol and triglycerides concentrations. The alpha lipoprotein concen-
trates can provide all cholesterol which is needed and in most cases all the protein and triglycerides as well. If not, then protein and triglycerides can be supplemented from the exogen¬ ous sources. Any other constituents that are present in insufficient concentration are then added as required. The pooled, adjusted serum is filled into vials, lyophilized and sealed.
The amount of concentrate to be added to the serum depend upon the amount of triglycerides and cholesterol present in the base serum and in the concentrate. These quantities can be measured conventionally and the proper quantity of concentrate to be added readily calculated. Since the concentrate is more suitable for cholesterol enhancement this will be the control¬ ling component. Generally, the high density lipoprotein con¬ centrate will contain about from 20% to 45% cholesterol by weight of lipoprotein, but this will vary depending upon the species from which the lipoprotein was obtained and the parti¬ cular lipoprotein fraction obtained by the concentration method employed in that particular instance.
The concentrate is typically added to bring the base serum cholesterol content at least up to the level of normal human serum, i.e. about from 1.2 to 2.5 g cholesterol (free plus ester)/ liter. Triglyceride should be brought up to about from 0.3 to 0.5 g/liter if possible without introducing more cho¬ lesterol than is desired. This invention has its principal utility in making hypercholesterolemic sera, i.e., sera in which the cholesterol content is about from 2^5 to 4.5 g/liter. Sera having
concentrations throughout this range may be lyophilized and reconstituted to optically satisfactory solutions.
The pooled animal sera produced by combining the above- described concentrates with an animal serum base contain a con¬ centration of lipoprotein lipid in excess of that found in pooled serum from animals of the same species. The composi¬ tions of this invention include pooled animal sera, particu¬ larly that from cattle and horses, which contain lipoprotein- bound cholesterol at a cholesterol concentration of greater than about 1.2g/l, preferably greater than about 2.0 g/1 and up to about 4.5g/1.
The novel products of this invention contain an enriched proportion of alpha lipoproteins, i.e., a proportion by weight of total lipoproteins and by weight/volume above that found in normal pooled serum and frequently a level above that in the serum of hyperσholesterolemiσ specimens of the animal in question. Frequently the alpha lipoprotein concentration will be in excess of 25% weight/volume above that of normal pooled plasma or serum. The level of alpha lipoprotein also may be described in terms of the weight ratio of alpha lipoproteins to beta and pre-beta lipoproteins. In the case of bovine sera, the ratio of alpha lipoproteins to beta and pre-beta lipopro¬ teins is at least 3.75:1, usually about 4:1. Sheep sera havin a ratio of at least 3.1 to 1, preferably about 3.5 to 1 are also useful but not as desirable as the more conveniently available bovine serum. The lipid, e.g. cholesterol concen¬ tration is generally at least about 25% by weight/volume above that of normal pooled plasma or serum.
- li ¬
lt is contemplated that cholesterol concentrates from on animal species can be added to a base serum of another animal. For example, bovine concentrates can be used with normal, pooled horse serum. While the products herein are preferably substantially free of human lipoproteins, contaminant human lipoproteins may accompany supplemental analytes such as human proteins added to adjust analyte concentrations as described above.
EXAMPLE The pH of a bovine alpha lipoprotein concentrate (Irvine Scientific) having a specific gravity of 1.008 and a choles¬ terol content of 1,322' mg/dl (DuPont ACA method) was adjusted to 8.0 by IN N OH. The concentrate had a specific gracity of 1.008 because it was not purified alpha lipoproteins; it con¬ tained a large proportion of bovine serum non-lipoprotein proteins. This conclusion was confirmed by electrophoresis in known fashion on a Sebia electrophoresis cell using a lipid- active gel and total protein electrophoresis using a Corning system. The pattern observed with the latter assay was consis tent with large amounts of non-lipoprotein proteins. The former assay demonstrated only a faint band at the very low density and chylomicron positions, but had a strong, broad stain identified as high density lipoprotein shading faintly into low density lipoprotein. This concentrate was clarified by filtration through a 0.3u pore diameter filter to a final volume of 49,800 ml.
- 12 -
648.2 liters of filtered bovine serum was mixed gently with the concentrate. The serum before adding the concen¬ trate had a cholesterol content of 118 mg/dl. The concentra¬ tion afterwards was 2.13 g/1. The product was filled into vials and lyophilized. Upon reconstitution it was of satis¬ factory clarity and no significant changes in clarity were observed after refrigerated storage for two days.
Claims
WE CLAIM:
1. A method for making quality control materials, com¬ prising combining a non-primate animal plasma or serum with non-primate animal alpha lipoproteins which are substantially free of chylomicrons and low density and very low density non- primate animal lipoproteins.
2. The method of Claim 1 wherein substantially no human lipoproteins are added to the quality control materials.
3. The method of Claim 1 wherein the plasma or serum is bovine.
4. The method of Claim 1 wherein the plasma or serum is equine.
5. The -method of Claim 1 wherein animal serum is com¬ bined with the alpha lipoproteins.
6. The method of Claims 3 or 4 wherein sufficient alpha lipoproteins are combined with the serum to produce a choles¬ terol concentration in the quality control material of about from 2.0 to 4.5 g/liter.
7. The method of Claim 6 wherein sufficient alpha lipo¬ proteins are combined to produce a cholesterol concentrate of about from 2.5 to 4.5 g/liter.
•gUR
O
_
- 14 -
8. The method of Claim 1 wherein the animal plasma or serum contains substantially normal concentrations of consti¬ tuents for the species from which the plasma or serum was obtained.
9. The method of Claim 5 wherein the serum is bovine and sufficient alpha lipoproteins are combined with the serum to produce at least a .3.75:1 ratio of alpha lipoproteins to the sum of beta and pre-beta lipoproteins.
10. The method of Claim 1 wherein the plasma or serum is a pool of plasma or serum donations from discrete donor indi¬ viduals.
11. The method of Claim 10 wherein sufficient alpha lipo¬ proteins are combined with the plasma or serum to produce a cholesterol concentration in the quality control material of about from 1.2 to 4.5 g/liter.
12. The method of Claim 1 wherein the serum or plasma is from different animal species than the alpha lipoprotein.
13. The method of Claim 10 wherein sufficient alpha lipoproteins are combined with the serum or plasma to produce quality control material having a cholesterol concentrate greater than that of normal pooled plasma or serum from the same species from which the serum of plasma originated.
14. The method of Claim 13 wherein the cholesterol con¬ centration is greater than about 25% above that of the normal pooled plasma or serum.
15. The method of Claim 10 wherein the alpha lipoprotein are combined with the serum or plasma to produce a quality con trol material having a weight of alpha lipoproteins/volume greater than that of normal pooled plasma or serum from the. same species.
16. The method of Claim 15 wherein the concentration of alpha lipoproteins is greater than about 25% above that of the normal pooled plasma or serum.
17. The method of Claim 1 wherein after combining the plasma or serum with animal alpha lipoproteins the level of non-lipid, clinically significant serum or plasma constituents is adjusted to within the range found in human serum and the adjusted plasma or serum lyophilized.
18. A quality control material comprising bovine serum and animal alpha lipoprotein, said material having at least a 3.75:1 ratio of alpha lipoproteins to the sum of beta and pre- beta lipoproteins.
19. A quality control material comprising animal serum or plasma,- and animal alpha lipoproteins, said material having a
O W
cholesterol concentration of about from 1.2 to 4.5 g/liter and being substantially free of human lipoproteins.
20. The material of Claim 19 wherein the serum or plasma is from a different animal species than the alpha lipoproteins.
21. A quality control material comprising animal serum o plasma, and animal alpha lipoproteins, said material having a cholesterol concentration greater than that of normal pooled plasma or serum from the same species from which the serum or plasma originated and being substantially free of human lipo¬ proteins.
22. The material of Claim 21 wherein the cholesterol con¬ centration is greater than about 25% above that of the normal pooled plasma or serum.
23. A quality control material comprising animal serum or plasma, and animal lipoproteins said material having a weight of alpha lipoproteins/volume greater than that of norma pooled plasma or serum from the same species from which the serum or plasma originated and being substantially free of human lipoproteins.
24. The material of Claim 23 wherein the concentration o alpha lipoproteins is greater than about 25% above that of the normal pooled plasma or serum.
25. The material of Claims 18, 19, 21 or 23 which con¬ tains levels of non-lipid, clinically significant serum or plasma constituents at a level within the range found in human serum and which is dry.
O
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37032482A | 1982-04-20 | 1982-04-20 | |
| US370324 | 1982-04-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0105923A1 EP0105923A1 (en) | 1984-04-25 |
| EP0105923A4 true EP0105923A4 (en) | 1984-09-06 |
Family
ID=23459173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19830901778 Withdrawn EP0105923A4 (en) | 1982-04-20 | 1983-04-20 | Method and composition for elevated lipid quality control materials. |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP0105923A4 (en) |
| WO (1) | WO1983003680A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4626511A (en) * | 1985-05-13 | 1986-12-02 | Wayne State University | Composition for reducing turbidity in samples of biological fluids |
| CA2148971A1 (en) * | 1994-05-26 | 1995-11-27 | Izak Bahar | Calibrator matrix |
| CN111295094A (en) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | Freeze-drying container and method for using freeze-drying container |
| JP2022525742A (en) | 2019-03-14 | 2022-05-19 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | Freeze-drying loading tray assembly and system |
| CN117554151B (en) * | 2024-01-11 | 2024-04-30 | 复星诊断科技(长沙)有限公司 | Cholesterol quality control liquid and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4045176A (en) * | 1975-06-13 | 1977-08-30 | Proksch Gary J | Preparation of optically clear serum |
| US4216117A (en) * | 1978-05-15 | 1980-08-05 | Bonderman Dean P | Lipoprotein diluent or solution and method useful in the preparation of assay reference materials |
| EP0031955A1 (en) * | 1980-01-07 | 1981-07-15 | Miles Laboratories, Inc. | Process for purification of lipoprotein cholesterol for use as a cholesterol reference material |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3764556A (en) * | 1971-02-02 | 1973-10-09 | Us Health Education & Welfare | Alcoholic precipitation and 1000x centrifugation preparation of hypercholesterolemic and hypertriglyceridemic sera as lipid determination control |
-
1983
- 1983-04-20 EP EP19830901778 patent/EP0105923A4/en not_active Withdrawn
- 1983-04-20 WO PCT/US1983/000571 patent/WO1983003680A1/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4045176A (en) * | 1975-06-13 | 1977-08-30 | Proksch Gary J | Preparation of optically clear serum |
| US4216117A (en) * | 1978-05-15 | 1980-08-05 | Bonderman Dean P | Lipoprotein diluent or solution and method useful in the preparation of assay reference materials |
| EP0031955A1 (en) * | 1980-01-07 | 1981-07-15 | Miles Laboratories, Inc. | Process for purification of lipoprotein cholesterol for use as a cholesterol reference material |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO8303680A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1983003680A1 (en) | 1983-10-27 |
| EP0105923A1 (en) | 1984-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4045176A (en) | Preparation of optically clear serum | |
| DE2258822A1 (en) | METHODS AND MEANS OF ANALYSIS OF ISOENZYME PATTERNS | |
| Pablo et al. | Insulin antibodies retard and insulin accelerates growth and differentiation in early embryos | |
| Ryan et al. | Lipid transfer protein from Manducasexta hemolymph | |
| CN107748267A (en) | One kind measure activated partial thromboplastin time（APTT）Kit | |
| US4211530A (en) | Test-kit and method for the estimation of LP-X | |
| EP0032204A1 (en) | Process and reagent for the immunological determination of enzymes | |
| EP0127603A2 (en) | Process for the preparation of a composition containing a factor VIII(AHF) | |
| EP0105923A4 (en) | Method and composition for elevated lipid quality control materials. | |
| JPH0666811A (en) | Manufacture of serum intermediate body | |
| US3764556A (en) | Alcoholic precipitation and 1000x centrifugation preparation of hypercholesterolemic and hypertriglyceridemic sera as lipid determination control | |
| US20030080056A1 (en) | Extraction of biological components from body fluids | |
| Proksch et al. | Preparation of optically clear lyophilized human serum for use in preparing control material. | |
| Stanojević-Paović et al. | Macro-and microelements in the cataractous eye lens | |
| Casillas et al. | Chromatographic behaviour of clotting factors | |
| US20210072266A1 (en) | Non-recombinant human insulin-like growth factor binding protein concentrate | |
| US3993585A (en) | Elevated human lipids control | |
| EP0337467B1 (en) | Method for the determination of thyroxine and a standard solution therefore | |
| JPH0345793B2 (en) | ||
| AT403437B (en) | PHYSIOLOGICALLY ACTIVE TISSUE FACTOR PREPARATION | |
| JPS58404B2 (en) | Method for producing steroid-binding globulin | |
| Kuchmak et al. | Preparation of reference sera with desired levels of cholesterol and triglyceride | |
| Kabayo | The nature of the nutritional importance of serum albumin to Glossina morsitans | |
| EP0013306B1 (en) | Process for the determination of an opsonic surface-binding alpha-2-glycoprotein | |
| Wallwork | Appraisal of the methodology and applications for measurement of the zinc content of blood components as indicators of zinc status |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19840326 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19851030 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LOFINK, GEORGE J. |